Novo Nordisk
750.9
DKK
+4.03 %
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
202 following
+4.03%
-6.25%
-18.51%
-18.65%
+7.56%
+7.16%
+99.89%
+313.95%
+60,213.25%
www.novonordisk.com
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Revenue
232.26B
EBIT %
44.16 %
P/E
40.22
Dividend yield-%
1.25 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
NOVO B
Daily low / high price
720.4 / 750.9
DKK
Market cap
3.35T DKK
Turnover
2.15B DKK
Volume
2.9M
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Novo Holdings AS | 28.3 % | 76.8 % |
ShowingAll content types
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
